<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04080622</url>
  </required_header>
  <id_info>
    <org_study_id>2018-005033-21</org_study_id>
    <nct_id>NCT04080622</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy of Selenium for the Prevention of Chemotherapy-induced Mucositis During Autologous Stem Cell Transplantation.</brief_title>
  <acronym>AutoSelenium</acronym>
  <official_title>A Randomized Trial to Evaluate the Efficacy of Selenium for the Prevention of Chemotherapy-induced Mucositis During Autologous Stem Cell Transplantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chemotherapy-induced mucositis is an important complication after autologous stem cell
      transplantation. It is mainly responsible for pain and dysphagia requiring opioids and
      artificial nutrition. It can also induce infectious complications. A few medication has
      demonstrated efficacy in this setting. It has been suggested that selenium can reduce the
      intensity of mucositis due to its antioxydant activity. The investigators therefore perform a
      randomized study to confirm this preliminary data.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of severe oral mucositis (grade 3-4)</measure>
    <time_frame>31 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of any grade oral mucositis</measure>
    <time_frame>31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with severe oral mucositis</measure>
    <time_frame>31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infectious complications</measure>
    <time_frame>31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with artifical nutrition</measure>
    <time_frame>31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with opioids</measure>
    <time_frame>31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>31 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Mucositis Oral</condition>
  <condition>Stem Cell Transplant Complications</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Usual care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selenium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual care + selenium 300 µg/day (IV infusion)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selenium</intervention_name>
    <description>Selenium 300 µg/day (IV infusion)</description>
    <arm_group_label>Selenium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>NaCl 0,9% (IV infusion)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients receiving autologous stem cell transplantation for lymphoma or myeloma.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Autologous stem cell transplantation for another medical condition than lymphoma or
             myéloma.

          -  Intolerance to selenium.

          -  High selenium levels before study.

          -  Pregnancy or patients breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Corentin Orvain, MD</last_name>
    <phone>33241354475</phone>
    <email>corentin.orvain@chu-angers.fr</email>
  </overall_contact>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 2, 2019</study_first_submitted>
  <study_first_submitted_qc>September 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>September 5, 2019</last_update_submitted>
  <last_update_submitted_qc>September 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

